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Abstract
Background: Human papillomaviruses are the most common sexually transmitted infections, and genital warts,
caused by HPV-6 and 11, entail considerable morbidity and cost. The natural history of genital warts in relation to
HIV-1 infection has not been described in African women. We examined risk factors for genital warts in a cohort of
high-risk women in Burkina Faso, in order to further describe their epidemiology.
Methods: A prospective study of 765 high-risk women who were followed at 4-monthly intervals for 27 months in
Burkina Faso. Logistic and Cox regression were used to identify factors associated with prevalent, incident and
persistent genital warts, including HIV-1 serostatus, CD4+ count, and concurrent sexually transmitted infections. In a
subset of 306 women, cervical HPV DNA was tested at enrolment.
Results: Genital wart prevalence at baseline was 1.6% (8/492) among HIV-uninfected and 7.0% (19/273) among
HIV-1 seropositive women. Forty women (5.2%) experienced at least one incident GW episode. Incidence was 1.1
per 100 person-years among HIV-uninfected women, 7.4 per 100 person-years among HIV-1 seropositive women
with a nadir CD4+ count >200 cells/μL and 14.6 per 100 person-years among HIV-1 seropositive women with a
nadir CD4+ count ≤200 cells/μL. Incident genital warts were also associated with concurrent bacterial vaginosis,
and genital ulceration. Antiretroviral therapy was not protective against incident or persistent genital warts.
Detection of HPV-6 DNA and abnormal cervical cytology were strongly associated with incident genital warts.
Conclusions: Genital warts occur much more frequently among HIV-1 infected women in Africa, particularly
among those with low CD4+ counts. Antiretroviral therapy did not reduce the incidence or persistence of genital
warts in this population.
Background
Human papillomaviruses (HPV) are the most common
sexually transmitted infections (STI) worldwide, although
they are often asymptomatic [1]. HPV infection is usually
transient, [2] but persistence depends on HPV type and
host immune status [3,4]. HPV types are divided into
high-risk (HR-HPV)and low-risk (LR-HPV), depending
on their potential for causing cervical and other ano-gen-
ital cancers [5]. The LR-HPV types HPV-6 and HPV-11
cause significant morbidity as the predominant causes of
genital warts (GWs) [6,7]. Comparatively little is known
about the epidemiology and natural history of LR-HPV
infection and GWs in sub-Saharan Africa. LR-HPV pre-
valence shows considerable regional variation, such as
11% in the Gambia, [8] or 28% in Tanzania, [9] and is
higher among individuals infected with the human
immunodeficiency virus (HIV) [10].
HIV infection is known to alter the natural history of
HPV infection. Patients co-infected with HIV-1 and
HPV have a greater likelihood of HPV progression, with
an increased risk for development of cervical neoplasia
in immunosuppressed women [11]. HIV-1 infected
patients with GWs can experience florid and prolonged
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T-lymphocyte response and other forms of immune dys-
function [12,13]. Low CD4+ count (≤200 cells/μL) is the
strongest independent predictor of infection with HR-
HPV genotypes and is also associated with an increased
risk of GWs [13,14]. The impact of highly active antire-
troviral therapy (HAART) on GWs remains uncertain,
with different statistical designs revealing different
effects on incidence and persistence [3,15]. Other possi-
bly contributing factors to GWs, such as other sexually
transmitted or reproductive tract infections (STI/RTI),
are poorly understood. Some studies suggest that STI/
RTI increase the acquisition of HPV. However, these
data are limited and predominantly from Western popu-
lations [13,15].
We have established a cohort of women at high risk
for HIV and other STI/RTI in Burkina Faso, providing
an opportunity to examine the epidemiology of various
STI/RTI over a three-year period. The aims of this
s t u d yw e r et od e t e r m i n et h ep r e v a l e n c e ,i n c i d e n c ea n d
persistence of GWs, and their association with HIV
infection, immunosuppression, and other risk factors in
an African setting.
Methods
Participants and study procedures
The Yérélon Cohort was established in 1998 to examine
factors associated with HIV infection among profes-
sional female sex workers and other high-risk women in
Burkina Faso and to design interventions to prevent
infection. A new phase of enrolment began in December
2003 and continued until January 2005. Women were
eligible for enrolment if they declared a history of at
least one transactional sex act per week, were aged
16 years or older, and were willing to undergo HIV test-
ing. Some women were recruited from local organiza-
tions for people living with HIV/AIDS, using the same
criteria. All women provided written informed consent.
The Yérélon Cohort research protocol was approved by
the institutional review board at Centre Muraz, and the
research ethics committees at the Burkina Faso Ministry
of Health and the London School of Hygiene & Tropical
Medicine.
Participants were followed approximately every
4 months until February 2006 for a maximum of 6 fol-
low-up visits. At enrolment, an interviewer adminis-
tered a questionnaire eliciting socio-demographic and
behavioral characteristics, and sexual health informa-
tion. At subsequent visits, intervening behavioral, sex-
ual health and treatment information was collected. At
all visits a study clinician performed a full physical
exam and collected genital samples. Clinicians docu-
mented the presence of abnormal discharge, genital
ulcers, and GWs, which were defined as a genital
proliferation with the clinical appearance of condylo-
mata acuminata [15]. The genital sites were described
as the cervix, vagina, labia, or ‘external’ (outer pubic and
anal) areas. Patients were treated for STI/RTI according
to national guidelines; there was no treatment available
for GWs. Since April 2004, HIV-infected participants
meeting the World Health Organization (WHO) elig-
ibility criteria for HAART initiation in developing coun-
tries have been provided with antiretrovirals [16].
Women with HIV clinical stages III or IV or with a
CD4+ count ≤200 cells/μL were treated with standard
antiretroviral therapy, primarily zidovudine (AZT),
lamivudine (3TC) and efavirenz (EFV). Women already
on HAART at the enrolment visit had been provided
with medications at the Bobo-Dioulasso University
Hospital.
Laboratory investigations
Vaginal smears were examined using wet-mount micro-
scopy to detect Trichomonas vaginalis (TV) and Gram-
stained to diagnose bacterial vaginosis (BV) [17].
Diagnosis of Neisseria gonorrhoeae w a sm a d eb yc u l t u r e
of cervical swabs using modified Thayer-Martin media.
Chlamydia trachomatis diagnosis could not be per-
formed during the study, but has been shown to be rare
in this population [18].
Blood samples were collected at enrolment and then
every 4 months. Syphilis serostatus was determined
every 12 months using the rapid plasma reagin test
(RPR, Human GmbH) confirmed with a Treponema
pallidum haemagglutination assay (TPHA, Newmarket
Laboratories). HSV-2 serology was done using the
Kalon IgG2-ELISA test (Kalon Biologicals). HIV serol-
ogy was done at enrolment and every 4 months among
seronegative women using a Determine-1/2 rapid test-
ing kit (Abbott Laboratories) with Genie-II (Bio-Rad
Laboratories) confirmation. CD4+ counts were deter-
mined using FACScan (Becton Dickinson) at enrol-
ment and every 6 months among HIV-1 seropositive
women; plasma HIV-1 RNA was quantified every 6 to
12 months using real-time PCR with a lower limit of
detection of 300 (2.48 log10 ) copies/mL [19]. Values
were converted to log10 copies/mL; those below the
threshold of detection were assigned a value of half the
threshold.
A subset of women enrolled between December 2003
and March 2004 submitted an additional cervical swab
at enrolment for HPV DNA detection and liquid-based
cytology using a Cervex swab and the ThinPrep 2000
processor (Cytyc Corporation) [10]. HPV genotyping
was performed using the INNO-LiPA genotyping v2 test
(Innogenetics) [20]. The 2001 Bethesda classification
was used for Papanicolaou-stained cervical slides inter-
pretation [21].
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Prevalent GWs were defined as the presence of clini-
cally-defined condylomata acuminata at the enrolment
visit. Due to the small number of women with CD4+
counts at the enrolment visit, women were classified as
HIV seronegative and HIV-1 seropositive at baseline.
Incident GWs were defined as the first documented
occurrence of condylomata acuminata in a previously
undocumented site after the enrolment visit. Women
with a GW in one location who developed a lesion in a
new location were included as a new incident event.
Persistent GWs were defined as GWs present in the
same anatomical site for at least two consecutive visits,
which could include the enrolment visit. Women were
stratified during study follow-up according to their
nadir CD4+ count in the following categories: (i) HIV-
negative, (ii) HIV-1 positive with a nadir CD4+ count
>200 cells/μL, and (iii) HIV-1 positive with a nadir CD4
+ count ≤200 cells/μL.
Statistical analysis
Analyses examined the association between HIV status
and other potential risk factors with prevalent GWs.
Univariate associations were examined using chi-
squared tests for categorical variables and two-sample
t-tests for continuous variables. Due to the strong
associations between many of our variables of interest,
a multivariate logistic regression model was developed
in a stepwise fashion including HIV status and risk
factors either decided a priori or independently asso-
ciated with prevalent GWs using p < 0.05 as the inclu-
sion criterion.
We measured incidence and persistence of GWs and
determined associations of potential risk factors with
these outcomes using Cox regression. To allow for
intra-subject correlation, these models used shared
frailty [22]. Other potential risk factors included time-
updated measures, such as concurrent STI/RTI, use of
HAART, and behavioral measures recorded at follow-up
visits. In order to establish the most likely ordering of
events, measures of behavior and confirmed STI/RTI
over the preceding period were taken from the visit at
which incident or persistent GWs were identified and
serological time-updated measures were taken from the
visit preceding any visit at which a new GW was identi-
fied. For HIV-1 seropositive women, a separate model
was constructed which included CD4+ count and
HAART use at the prior visit and maximum viral load
during the study period. Nadir CD4+ count was not
included in these models because model convergence
could not be achieved.
Further analyses were conducted to examine the asso-
ciation of cervical HPV and squamous intraepithelial
lesions (SIL) with incident GWs among women from
whom cervical HPV DNA had been collected, using the
same methods as above to construct the final model.
The effect of time in the study was assessed for each
variable in all models and an interaction parameter was
included if the hazard ratio changed significantly after
one year of follow-up.
Statistical analyses were performed using Stata ver-
sion10.0 (StataCorp).
Results
Characteristics of cohort participants
Overall, 767 women were enrolled in the Yérélon
Cohort study between December 2003 and January
2005, and followed up until February 2006. Two hun-
dred and sixty eight (34.9%) women were infected with
HIV-1 and five (0.7%) were co-infected with HIV-1 and
HIV-2. Two women were infected with HIV-2 alone,
and were excluded from analyses. Characteristics of
study participants at enrolment are presented in Table 1.
Overall mean age was 28 years (range, 15-54). The med-
ian follow-up time was 1.7 years (range 0-2.2 years). At
baseline, a quarter (24.7%, 66/267) of HIV-1 seropositive
women had a CD4+ count <200 cells/μL and 9.5%
(26/273) of women were on HAART. HIV-1 infected
women were significantly older, were more likely to have
been married, had fewer recent sexual partners and were
less likely to use hormonal contraception. No women
were infected with Neisseria gonorrhoeae.
In the analysis of the 306 women from whom cervical
cytological samples were collected, HIV-1 seropositive
women had significantly more cervical squamous intrae-
pithelial lesions than HIV-uninfected women (P < 0.001)
(Table 1). There were no cases of atypical squamous
cells-cannot exclude HSIL (ASC-H), atypical glandular
cells (AGC), or cancer identified.
Prevalent genital warts and associated risk factors
At enrolment, 27 women (3.5%) had GWs, 1.6% (8/492)
among HIV-uninfected and 7.0% (19/273) among HIV-1
seropositive women (P < 0.001) (Table 1). There were
no prevalent GWs among the 26 women taking
H A A R T .I nt h em u l t i v a r i a t ea n a l y s i s ,w h i c hi n c l u d e d
HSV-2 serostatus, the presence of bacterial vaginosis,
number of recent sexual partners and age group, there
was a 5-fold increase in risk for prevalent GWs in HIV-
1 seropositive women (adjusted odds ratio [aOR] 5.33,
95%CI: 1.97 to 14.40, P = 0.001). Women who smoked
had a 3-fold increased risk of prevalent GW (aOR 3.55,
95%CI: 1.03 to 12.32, P = 0.05). For HIV-1 seropositive
women, there was no evidence of a relationship between
CD4+ count and prevalence of GWs (CD4+ count >200
cells/μLv s .≤200 cells/μL, [aOR = 1.77, 95%CI: 0.36 to
8.61, P = 0.48). None of the other variables shown in
Table 1 were associated with prevalent GWs.
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Characteristic HIV seronegative (N = 492) n (%) HIV-1 seropositive (N = 273) n (%) P-value
a
Age groups, years (N = 759)
16-24 265 (54.1) 53 (19.7) <0.001
b
25-34 138 (28.2) 124 (46.1)
≥35 87 (17.8) 92 (34.2)
Education (N = 752)
None 189 (38.8) 116 (44.8) 0.19
Primary or above 298 (61.2) 149 (56.2)
Marital status (N = 754)
Widowed 14 (2.9) 55 (20.8) <0.001
a
Divorced/Separated 70 (14.3) 50 (18.9)
Married/cohabitating 88 (18.0) 58 (21.9)
Single 317 (64.8) 102 (38.5)
Age at first sex, median (IQR), years 16 (15-18) 16 (15-18) 0.42
b
Number of sex partners in last week (N = 752)
None 110 (22.5) 114 (43.2) <0.001
b
1-9 309 (63.3) 120 (45.5)
≥10 69 (14.1) 30 (11.4)
Currently smoking (N = 759) 25 (5.1) 19 (7.0) 0.30
Contraceptive use (N = 760)
Other/None 405 (83.2) 249 (91.2) 0.002
Hormonal contraception 68 (14.0) 19 (7.0)
Injectable contraception 14 (2.8) 5 (1.8)
Practices regular vaginal douching 424 (86.2) 222 (81.3) 0.24
Condom use with clients/partners (N = 751)
Sometimes/Never 177 (36.0) 98 (35.9)
Always 315 (64.0) 175 (64.1) 0.98
Current genital warts 8 (1.6) 19 (7.0) <0.001
Bacterial vaginosis (N = 718) 178 (37.2) 118 (49.2) 0.003
Trichomonas vaginalis (N = 596) 29 (7.2) 19 (9.6) 0.32
HSV-2 positive serology (N = 689) 226 (49.6) 204 (88.3) <0.001
Current antiretroviral therapy (HAART) 26 (9.5)
CD4+ count, cells/μL:
Not on HAART (N = 242)
>500 81 (33.5) 0.09
a,e
200-500 105 (43.4)
<200 56 (23.1)
On HAART (N = 25)
>500 4 (16.0)
200-500 11 (44.0)
<200 10 (40.0)
Plasma HIV-1 RNA, log10 copies/mL
d:
Not on HAART (N = 233)
≥2.48 204 (87.6) <0.001
a,e
<2.48 29 (12.4)
On HAART (N = 24)
≥2.48 7 (29.2)
<2.48 17 (70.82)
Cervical HPV-6 or -11 (N = 306)
f 13 (7.1) 15 (12.2) 0.13
LSIL (N = 306)
f 17 (9.4) 48 (41.4) <0.001
HSIL (N = 306)
f 1 (0.6) 11 (9.5)
IQR, interquartile range; HAART, highly active antiretroviral therapy; CI, confidence interval; HPV, human papillomavirus; LSIL/HSIL, low/high grade squamous
intraepithelial lesions.
a Determined by c
2 analysis;
b Determined by c
2 test of trend;
c Nonparametric equality of medians test;
d Lower limit of detection of HIV-1 PVL is 2.48 log10
copies/mL;
e Comparison of women on HAART vs not on HAART;
f Conducted in subset of women.
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Over the 27 months of the study, 16.9% (129/765) of
women were lost to follow-up. Twenty-one women
died, all of whom were HIV-1 seropositive. The percen-
tage of scheduled visits attended was 83.3%; this did not
differ by HIV-1 serostatus.
Forty women (5.2%) experienced at least one incident
GW episode for a total of 50 episodes. The most com-
mon sites for new lesions were the external genitalia
(including the perianal area) observed in 28 women.
GW incidence was 1.1 per 100 person-years among
HIV-uninfected women, 7.4 per 100 person-years
among HIV-1 seropositive women with a nadir CD4+
count >200 cells/μL and 14.6 per 100 person-years
among HIV-1 seropositive women with a nadir CD4+
count ≤200 cells/μL (Table 2). Incidence was 16.7 per
100 person-years for women on HAART.
In the multivariate model including all women, HIV-1
and nadir CD4+ count were the strongest predictors of
incident GWs. Compared to HIV-uninfected women,
HIV-1-seropositive women with a nadir CD4+ ≤200
cells/μL had an almost 20-fold higher risk of incident
GWs (adjusted hazard ratio [aHR] 19.13, 95%CI: 6.94 to
52.71, P < 0.001); among HIV-1-seropositive women
with CD4+ counts >200 cells/μL, the estimated risk was
6-fold higher (aHR 6.51, 95%CI: 2.38 to 17.78, P <
0.001). Having a primary education or above was protec-
tive (aHR 0.45, 95%CI: 0.23 to 0.88, P = 0.02). For the
time-updated variables, concurrent bacterial vaginosis
(aHR 2.17, 95%CI: 1.13 to 4.18, P = 0.02), and genital
ulceration (aHR 3.29, 95%CI: 1.13 to 9.55, P = 0.03)
were associated with incident GWs.
The model among HIV-1 seropositive women indi-
cated a trend towards a protective effect for increasing
CD4+ count at the prior visit (aHR 0.79 for each 100
cells/μL increase, 95%CI: 0.61 to 1.02, P = 0.07), but the
use of HAART per se was not protective. High maxi-
mum HIV-1 plasma viral load was predictive of incident
GWs, although this was not statistically significant.
There was no evidence of an interaction between nadir
CD4+ count and time since enrolment on incidence
of GWs.
Persistence of genital warts
In the absence of treatment, 40% of women with an
identified GW (16/40) had persistent warts at the next
visit. The strongest predictor of GW persistence was
HIV-1 status and nadir CD4+ count: GW persistence
was 0.4 per 100 person-years among HIV-uninfected
women, 6.1 per 100 person-years among HIV-1 seropo-
sitive women with nadir CD4+ counts >200 cells/μL,
and 13.4 per 100 person-years for those women with
nadir CD4+ counts ≤200 cells/μL. The multivariate
model among HIV-1 seropositive women indicated that
there was no protective effect of prior antiretroviral
treatment on persistence (aHR 1.71, 95%CI: 0.40 to 7.23,
P = 0.47), but there was weak evidence that a CD4+
count was protective (aHR 0.72 for each 100 cells/μL
increase, 95%CI: 0.45 to 1.14, P = 0.16). No other factors
were significantly associated with persistence of GWs.
Association of HPV-6 or -11 with incident genital warts
In the subgroup of 306 women with enrolment cytologi-
cal and HPV DNA samples, HPV-52, a HR-HPV, was
the most common HPV type, identified in 14.7% (45/
306) of women. LR-HPV prevalence was 32.7% (100/
306); the prevalence of HPV-6 and -11 were 6% (18/
306) and 4% (13/306), respectively, and 71% (20/28) of
women with HPV-6 or -11 were infected with more
than one type of HPV. Detection of cervical HPV-6
DNA was associated with prevalent GWs (aOR 4.12,
95%CI: 1.17 to 14.53, P = 0.03) and had a strong predic-
tive effect for incident GWs (aHR 9.09, 95% CI: 1.75 to
47.29, P = 0.009) during the first year of follow-up, com-
pared to those without HPV-6 (Table 3). In fact, 44.4%
(8/18) of the women who were positive for cervical
HPV-6 DNA had either a prevalent or incident GWs
during the study period. In the analysis of individual
HPV types, there was weak evidence of an association
between incident GWs and cervical HPV-52 DNA at
enrolment (aHR 3.81, 95% CI: 0.90 to 16.23, P = 0.07),
with one lesion occurring in a woman co-infected with
HPV-6. There was no evidence for any association
between GWs and other HPV types, including HPV-11,
although numbers were very small. The presence of
abnormal cervical cytology (LSIL or higher) at enrol-
ment was also predictive of incident GWs (aHR 3.05,
95% CI: 1.17 to 7.92, P = 0.02); these relationships did
not vary with time. None of the women negative for
HPV DNA at baseline had an incident event. The rela-
tionship between HIV-1 status and incident GWs per-
sisted after adjusting for the presence of HPV-6 or -11
at baseline. HAART did not protect against incident
lesions (aHR 1.03, 95%CI: 0.26 to 4.05, P = 0.96).
Discussion
This study provides the first longitudinal data on the
natural history of GWs among HIV infected women
in Africa. In this setting, we found an overall preva-
lence of GWs of 3.5%. This is consistent with GW
prevalence from other countries in Africa, [24]
although this depends on the region, prevalence of
HIV-1, and the sexual risk behaviours of studied
populations. The Women’s Interagency HIV Study in
the USA reported GW incidences of 2.2 per 100 per-
son-years in HIV-uninfected and 8.9 per 100 person-
years in HIV-1 seropositive women, which are similar
to our findings [13].
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and immune function, as measured by nadir CD4+
count, were the most powerful predictors of incident
and persistent GWs, [13,15] even after adjusting for the
presence of HPV. Although only partially understood,
GW regression is thought to be dependent upon the
cell-mediated immune response; CD4+ T-lymphocytes
have been shown to be present in large numbers in the
stroma under the lesions and in the regressing warts
themselves, but their role in clearance has not been
entirely elucidated [12,25]. In studies of canine oral
papillomavirus, it is the response of CD4+ cells to viral
Table 2 Univariate and multivariate assessment of factors associated with incident genital warts over three years
Characteristic Number of events/
person-years
Unadjusted HR
a
(95% CI)
Adjusted HR
b
(95% CI)
P-value
1. Among all women:
HIV status, nadir CD4+ count
HIV seronegative 8/756 1.0 1.0
HIV-1+, CD4 >200cells/μL 18/245 7.29 (3.0-17.70) 6.51 (2.38-17.78) <0.001
HIV-1+, CD4 ≤200 cells/μL 24/165 14.92 (6.21-35.85) 19.13 (6.94-52.71) <0.001
Enrolment variables:
Age groups, years
16-24 9/454 1.0 1.0
25-34 28/414 3.29 (1.40-7.74) 1.74 (0.69-4.42) 0.24
>34 13/294 2.19 (0.84-5.72) 0.83 (0.29-2.37) 0.73
Education
None 32/510 1.0
Primary/Above 18/655 0.43 (0.22-0.86) 0.45 (0.23-0.88) 0.02
Age at first sex, years
10-17 41/889 1.0
18-29 9/275 0.71 (0.30-1.67)
Smoking 5/63 1.76 (0.50-6.15) 1.56 (0.50-4.86) 0.44
HSV-2 positive serology 43/676 4.33 (1.81-10.38) 0.86 (0.31-2.38) 0.77
History of pregnancy 47/954 3.42 (0.96-12.16) 1.30 (0.33-5.11) 0.71
Concurrent variables:
Number of sex partners in past week
0 10/241 1.0 1.0
1-9 30/753 1.05 (0.48-2.27) 1.46 (0.66-3.22) 0.35
≥10 10/116 2.44 (0.85-7.05) 3.16 (1.11-8.95) 0.03
Contraceptive use
None/Other 40/958 1.0 1.0
Hormonal contraception 4/156 0.64 (0.21-1.94) 0.85 (0.28-2.61) 0.77
Injectable contraception 4/34 2.95 (0.81-10.75) 3.24 (0.91-11.51) 0.07
Practices regular vaginal douching 43/987 1.01 (0.33-3.11)
Condom use with clients/partners
Sometimes/Never 31/799 1.0
Always 19/311 1.75 (0.92-3.33)
Days since last menstruation
c
≤15 27/503 1.0
>15 14/415 0.69 (0.35-1.37)
Bacterial vaginosis 18/226 2.11 (1.12-4.00) 2.17 (1.13-4.18) 0.02
Trichomonas vaginalis 1/30 1.18 (0.13-10.53)
Genital ulceration 5/23 4.66 (1.55-14.03) 3.29 (1.13-9.55) 0.03
2. Among HIV-1 positive women only:
On HAART at prior visit 15/94 1.39 (0.66-2.95) 1.50 (0.61-3.70) 0.38
Highest log10 viral load in the past 3 years 1.35 (0.99-1.83) 1.13 (0.78-1.65) 0.51
CD4+ count at prior visit (per 100 cells/μL increase) 0.73 (0.57-0.93) 0.79 (0.61-1.02) 0.07
HR, hazard ratio; CI, confidence interval; HAART: highly active antiretroviral therapy.
a Determined by Cox regression with shared frailty;
b Adjusted for HIV-1 serostatus and nadir CD4+ count, age group, educational status, smoking, history of
pregnancy and HSV-2 serostatus at enrolment, and concurrent number of weekly sex partners, contraception, genital ulcerations and bacterial vaginosis;
c Women with amenorrhea and menopause were excluded from this group.
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lesions [26]. The strong association between concurrent
BV and genital ulceration and incident GWs supports a
common determinant. There is good evidence support-
ing the role of the vaginal flora in both susceptibility to
and clearance of infections, as HPV infects via micro-
abrasions in the genital mucosa [27].
This is the first study to evaluate the impact of
H A A R To nG W si nw o m e ni nA f r i c a .W ed i dn o t
detect any protective effecto fH A A R To ni n c i d e n c eo r
persistence, despite the overall excellent adherence
achieved in this cohort [28]. The burden of HR-HPV
was recently shown to be reduced by effective HAART,
[29] but the impact on LR-HPV is unknown, and its
effect on GWs varies between studies [3,15]. However,
our interpretation of these results is limited by the rela-
tively small number of visits for women on HAART,
and the partial data on concurrent CD4+ count and
HIV-1 viral loads.
We identified a strong association between detection
of cervical HPV-6 DNA and incident GWs in the first
year of follow-up. Our data also support studies demon-
strating a relative lack of epidemiological contribution of
HPV-11 in GWs [7,30]. HPV-52 has been identified as
one of the types most commonly identified in GWs in
conjunction with HPV-6 in Australia [7]. Furthermore, a
study of HPV in GWs in France demonstrated that 6.4%
of patients with GWs had HPV-52 on cytobrush sam-
pling [6]. It is probable that cervical HPV was only par-
tially representative of causative genotypes for GWs; the
trend towards an increase in GWs in women infected
with other types of HPV could reflect local but
undetected infection with HPV-6 or 11. Furthermore,
the small number of women infected with HPV-11 lim-
its the power of this study to detect an association.
However, as there are few studies examining the distri-
bution of HPV in GWs in Africa, it is possible that this
reflects a different epidemiology of HPV in this region
compared to other settings. Further studies with larger
numbers of women and direct sampling of warts for
HPV types are required to better understand this
relationship.
Study limitations include the varying time between
visits, and the broad categorization of anatomical loca-
tion which might have led to undetected new GWs and
thus an underestimate of incidence. Although rare in
this setting, it is also possible that some women sought
treatment for GWs elsewhere, which may have resulted
in underestimates of GW persistence.
Conclusions
This is the first study to examine the natural history of
genital warts in African women and the impact of HIV-
1 infection and HAART. This high-risk population with
high HIV prevalence and GW incidence and little access
to ablative therapy may contribute more to HPV trans-
mission and suffer disproportionately from the conse-
quences of HPV infection. We have demonstrated a
high incidence of genital warts in this population, and a
very strong association with immune suppression from
HIV-1 infection; there was no protective effect from
HAART. This and other epidemiological studies of HPV
types in different populations should inform further vac-
cine development designed for African women.
Table 3 Associations between cervical HPV DNA, HIV-1 serostatus and cytology and incident genital warts among a
sub-group of 306 women
Characteristic Number of events/person-years Unadjusted HR
a (95% CI) Adjusted HR
b (95% CI) P-value
Cervical HPV DNA at baseline
HPV-6 positive, yes vs. no
Effect in 1
st year of follow-up 4/17 8.67 (1.86-40.40) 9.09 (1.75-47.29) 0.009
Effect after 1
st year of follow-up 1/12 0.12 (0.03-0.54) 0.11 (0.02-0.57) 0.009
HPV-11 positive, yes vs. no 1/21 0.74 (0.07-7.58) 1.17 (0.11-12.37) 0.89
HPV-52 positive, yes vs. no 9/50 3.73 (1.28-10.83) 3.81 (0.90-16.23) 0.07
Other HPV types, negative for types 6, 11,52 19/226 1.48 (0.64-3.45) 2.64 (0.62-11.33) 0.19
Cervical cytology at baseline (N = 296)
Normal 9/369 1.0 1.0
ASCUS/LSIL/HSIL 23/134 7.38 (3.10-17.56) 3.05 (1.17-7.92) 0.02
HIV status, nadir CD4+ count
HIV seronegative 4/289 1.0
HIV-1+, CD4 >200cells/μL 11/119 3.22 (0.71-14.59) 0.13
HIV-1+, CD4 ≤200 cells/μL 18/79 10.94 (2.60-46.12) 0.001
Note. HR: hazard ratio; CI, confidence interval; ASCUS, atypical squamous changes of unknown significance; LSIL/HSIL, low/high squamous intraepithelial lesions.
a Determined by Cox regression with shared frailty;
b Model also included age group, history of pregnancy, history of smoking, hormonal contraception,
education less than or greater than primary and number of sexual partners in past week. For those factors not conforming to proportional hazards, a parameter
was added to determine the impact in the first year of follow-up compared to after one year.
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